Business Wire

Hisense Donates Leading Quality Devices to PARIS-SAINT-GERMAIN Endowment Fund, Making the World a Better Place Through Charity

Share

Hisense, a leading technology enterprise worldwide, became a global partner with Paris Saint-Germain in 2020. Since then, benefiting from this partnership, Hisense has gained much recognition and support from consumers and built stronger emotional connections with football fans worldwide. As a socially responsible enterprise, Hisense took a step further and elevated its partnership by donating multiple hi-tech devices to non-profit programs and became a patron of Paris Saint-Germain Endowment Fund.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220423005007/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Cantine Solidaire (Photo: Business Wire)

Hisense Donated TVs to Fully Support and Nurture Youth Development

Hisense donated TVs to the Paris Saint-Germain Endowment Fund; these TVs were used in the Cantine Solidaire organized by the Paris Saint-Germain Endowment Fund in March 2022, where 200 teenagers were welcomed to the Parc des Princes. The event focused on equality, sport, culture, digital world, citizenship, and music with students treated to lunch and sports and leisure activities and a CV workshop.

Sabrina Delannoy, Deputy Director of the Paris Saint-Germain Endowment Fund, commented on this partnership: "We are delighted that the club's partners are interested in our projects and are committed to supporting us. It shows that members of the Paris Saint-Germain family share our values. Hisense is an example for others to follow, we hope to continue working altogether in the long-term."

Hisense to Fulfill Corporate Social Responsibility, Aims to Create a Better Sustainable World

Cédric Audebert, Vice President of Hisense France, said: "As a partner of Paris Saint-Germain, we are very interested in the social initiatives of the Paris Saint-Germain Endowment Fund. Sport is a means of sharing and expressing solidarity, two values that are essential to us. Our goal is to show unstinting support for Paris Saint-Germain Endowment Fund, and we urge all companies to come and join us."

Hisense devotes to charity and sustainable development worldwide, it has donated many high-tech home appliances exclusively for Paris Saint-Germain Endowment Fund programs. As part of the above donation, Hisense donated TVs for "PSG HOLIDAYS," provided better equipment for children to have better training experience; also, Hisense donated a large screen TV for ‘Red & Blue School program’, provided long-term support and better environment for after-school training.

Hisense has been upholding the people-oriented concept, actively supporting charities, focusing on social responsibility and striving to make new contributions to global sustainable development.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Caroline Chen
Hisense PR Team
hisenseglobal@ogilvy.com
+8613922322347

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination

Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib

New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release

Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet

Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release

On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan

Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release

Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of